Engineering NK92 cells with an anti-CD19 CAR construct that incorporates a CD3ζ signaling domain either alone or with additional costimulatory molecules (e.g., CD28, 4-1BB, or 2B4) could achieve significant cytotoxicity of NK cells towards B-cell leukemic cell lines and NK-resistant primary leukemia cells in vitro (64, 75–77). The gene discussed is CD19; the disease is leukemia.